Cerevel Therapeutics (CERE) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
02M5M8M10M12M15M18M20MQ1 2023Q2 2023Q3 2023Q4 2023Q1 2024

Margin (%)

Gross MarginOperating MarginNet Income Margin
012253850627588100Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024

Operating Expenses

Research And Development ExpensesSelling And Marketing ExpensesGeneral And Administrative ExpensesOther Expenses
025M50M75M100M125M150M175M200MQ1 2023Q2 2023Q3 2023Q4 2023Q1 2024

EBITDA

EBITDA
-200M-175M-150M-125M-100M-75M-50M-25M1Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024

EPS

Revenue Variation (%)

Revenue Variation
-200-175-150-125-100-74-49-241Q1 2024

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
01020304050607080Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024

Revenue YoY Variation (%)

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
0255075100125150175200Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024

Price-to-Earning Ratio

P/E Ratio
-20-17-15-12-10-7-4-21Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024

Income Breakdown

Per Share Metrics

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
04M8M11M15M19M22M26M30MQ1 2023Q2 2023Q3 2023Q4 2023Q1 2024

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000001111Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024
💰 Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
02581012151820Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024

Free Cash Flow

Cash Flow to Debt Ratio

Cash At End Of Period
0250M500M750M1B1B2B2B2BQ1 2023Q2 2023Q3 2023Q4 2023Q1 2024
🏦 Balance Sheet
📈 Key Metrics